Table 2 Characteristics of AAS use in the study group at the time of inclusion
From: Recruitment to doping and help-seeking behavior of eight female AAS users
Subject | Age | Self- Reported, AAS/clenbuterol | Identified in urine analysis | Last Intake (weeks) | Duration of AAS use | Other doping agents used | Reported Narcotics | Urine analysis |
|---|---|---|---|---|---|---|---|---|
K1 | 24 | Primobolan, Winstrol | methenolone (1621 ng/mL) stanozolol (116 ng/mL) | 3 | 2 years | Cannabis | Cannabis | |
K2 | 27 | Clenbuterol | clenbuterol (42 ng/mL) | 0a | 8 months | None | Negative | |
K3 | 29 | Clenbuterol | Negative | 1 | 3.5 months | ephedrine | None | Negative |
K4 | 31 | Winstrol, Primobolan | stanozolol (56.8 ng/mL) nandrolone (17.4 ng/mL) | 14 | 2 years | Growth hormone, ephedrine | None | Negative |
K5 | 20 | Winstrol | Negative | 25 | 7 weeks | Cocaine | Negative | |
K6 | 16 | Clenbuterol | Negative | 12 | 3 years | ephedrine | None | Negative |
K7 | 21 | Metandrostenolone, Deca-Durabol, Clenbuterol | Negative | 1 | 2 years | ephedrine | None | Negative |
K8 | 16 | Deca-Durabol, Stanozolol, clenbuterol | nandrolone (4947 ng/mL) stanozolol (84 ng/mL) | 5 | 1 year | ephedrine | Cannabis | Cannabis |